Pharmacological Agents in the Sleeping Disorder

Sleep disorders, are involved insomnia, restless legs syndrome (RLS), narcolepsy, and obstructive sleep apnea (OSA), affect millions worldwide, significantly impacting health and quality of life. Pharmacological treatment remains a cornerstone in the management of these conditions, with diverse agents targeting different pathways. This review provides a comprehensive examination of the pharmacological agents used in treating sleep disorders, covering their mechanisms of action, efficacy, safety, and clinical application. Additionally, it highlights emerging therapies and future next way in the field.

Sleep disorder, Insomnia, obstructive sleep apnea, RLS, narcolepsy Pharmacological agents, Therapeutic effect of Drugs, Special Indications.

1. K. Pavlova M, Latreille V. Sleep Disorders. Am J Med. 2019;132(3):292-299. doi:10.1016/j.amjmed.2018.09.021 [Google Scholar] [Crossref]

2. Laratta CR, Ayas NT, Povitz M, Pendharkar SR. Diagnosis and treatment of obstructive sleep apnea in adults. Cmaj. 2017;189(48):E1481-E1488. doi:10.1503/cmaj.170296 [Google Scholar] [Crossref]

3. España RA, Scammell TE. Sleep Neurobiology from a Clinical Perspective. 2011;34(7). doi:10.5665/SLEEP.1112 [Google Scholar] [Crossref]

4. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012: Practice parameters with an evidence-based systematic review and meta-analyses. Sleep. 2012;35(8):1039-1062. doi:10.5665/sleep.1988 [Google Scholar] [Crossref]

5. Park EJ, Park Y min. Opioid Withdrawal and Restless Legs Syndrome. 2020;2(4):137-140. [Google Scholar] [Crossref]

6. Lai SC, Chen RS. Restless legs syndrome. Acta Neurol Taiwan. 2008;17(1):54-65. [Google Scholar] [Crossref]

7. Sateia MJ. International classification of sleep disorders-third edition highlights and modifications. Chest. 2014;146(5):1387-1394. doi:10.1378/chest.14-0970 [Google Scholar] [Crossref]

8. Guo F, Yi L, Zhang W, Bian Z jie, Zhang Y bo. and Risk of Cognitive Impairment in Middle-Aged and Older Patients With Chronic Insomnia. 2021;15(December):1-8. doi:10.3389/fnhum.2021.775144 [Google Scholar] [Crossref]

9. Ac ce pt Pa pe. [Google Scholar] [Crossref]

10. Del A, Verduzco R, Salari A, Haghparast P. Efficacy and safety of pharmacotherapy in chronic insomnia : A review of clinical guidelines and case reports Insomnia Pharmacotherapy and Adverse E ff ects Overview. Published online 2024. doi:10.9740/mhc.2023.10.244 [Google Scholar] [Crossref]

11. Drover DR. Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives. 2004;43(4):227-238. [Google Scholar] [Crossref]

12. Tsai M jun, Tsai Y hung, Huang Y bin. Compulsive activity and anterograde amnesia after zolpidem use. 2007;(91):179-181. doi:10.1080/15563650600956741 [Google Scholar] [Crossref]

13. Scharner V, Hasieber L, Sönnichsen A, Mann E. Efficacy and safety of Z-substances in the management of insomnia in older adults : a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. Published online 2022:1-19. doi:10.1186/s12877-022-02757-6 [Google Scholar] [Crossref]

14. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology . LXXV . Nomenclature , Classification , and Pharmacology of G Protein-Coupled Melatonin Receptors. 2010;62(3):343-380. doi:10.1124/pr.110.002832.343 [Google Scholar] [Crossref]

15. Roecker AJ, Coleman PJ. Orexin Receptor Antagonists : Medicinal Chemistry and Therapeutic Potential. Published online 2008:977-987. [Google Scholar] [Crossref]

16. Stahl SM. BRAINSTORMS — Clinical Neuroscience Update Mechanism of action of suvorexant BRAINSTORMS — Clinical Neuroscience Update. 2017;36(2016):1769-1772. doi:10.1017/S1092852916000225 [Google Scholar] [Crossref]

17. Wisor J, Mistlberger RE, Fraser S. Modafinil as a catecholaminergic agent : empirical evidence and unanswered questions. 2013;4(October):1-10. doi:10.3389/fneur.2013.00139 [Google Scholar] [Crossref]

18. Ishizuka T, Murotani T, Yamatodani A. Action of Modafinil Through Histaminergic and Orexinergic Neurons. Vol 89. 1st ed. Elsevier Inc. doi:10.1016/B978-0-12-394623-2.00014-7 [Google Scholar] [Crossref]

19. Jr PR, Hellriegel ET. Profile of Modafinil. 2003;42(2):123-137. [Google Scholar] [Crossref]

20. Schwartz JRL, Feldman NT, Fry JM, Harsh J. Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. 2003;4:43-49. doi:10.1016/S1 [Google Scholar] [Crossref]

21. Roth T, Dauvilliers Y, Guinta D. Sodium oxybate and narcolepsy Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. Published online 2017:407-414. doi:10.1111/jsr.12468 [Google Scholar] [Crossref]

22. Sanap GS. International Journal of Research Publication and Reviews Therapeutic Role of Euphorbia Nerifolia their Active Constituents and Pharmacological Activity in Disease prevention and T ... International Journal of Research Publication and Reviews Therapeutic . 2024;4(April 2023):1584-1595. [Google Scholar] [Crossref]

23. Van W, Addolorato G, Aubin H jean, et al. Ef fi cacy and safety of sodium oxybate in alcohol- dependent patients with a very high drinking risk level. :969-986. doi:10.1111/adb.12645 [Google Scholar] [Crossref]

24. Miskoff JA, Chaudhri M. Off-label Sodium Oxybate in Childhood Narcolepsy : A Comprehensive Report. 2018;10(4):5-9. doi:10.7759/cureus.2526 [Google Scholar] [Crossref]

25. Drakatos P, Lykouras D, D’Ancona G, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017;35:80-84. doi:10.1016/j.sleep.2017.03.028 [Google Scholar] [Crossref]

26. Lm T, La B. Iron for the treatment of restless legs syndrome (Review). Published online 2019. doi:10.1002/14651858.CD007834.pub3.www.cochranelibrary.com [Google Scholar] [Crossref]

27. D LIVP, D NA agugua P, D JCP, et al. Critical review of ropinirole and pramipexole – putative dopamine D 3 -receptor selective agonists – for the treatment of RLS. 2009;(November 2008):493-505. doi:10.1111/j.1365-2710.2009.01025.x [Google Scholar] [Crossref]

28. I PAIHIL, Eh CHIHUY, Ang SHUEIW. ● Original Contribution. 2002;28(3):349-358. [Google Scholar] [Crossref]

29. Merlino G, Serafi A, Robiony F, Valente M, Gigli GL. Clinical experience with pramipexole in the treatment. Published online 2008. [Google Scholar] [Crossref]

30. Warot D, Mazet P. After 11 Years of Treatment in Parkinson ’ s Disease T O THE E DITOR : T h e d r u g 5 - m e t h ox y- N , N - d i i s o p ro py l -. 2005;(April):292-293. [Google Scholar] [Crossref]

31. Randomized A. Safety and Efficacy of Pramipexole in Early Parkinson Disease. [Google Scholar] [Crossref]

32. Chincholkar M. Gabapentinoids : pharmacokinetics , pharmacodynamics and considerations for clinical practice. Published online 2020. doi:10.1177/2049463720912496 [Google Scholar] [Crossref]

33. Us T, Group S. The long-term safety and efficacy of gabapentin ( Neurontin @) as add-on therapy in drug-resistant partial epilepsy. 1994;8:67-73. [Google Scholar] [Crossref]

34. Opposite effects of Is and K opiates on the firing-rate of dopamine cells in the substantia nigra of the rat. 1987;134:53-59. [Google Scholar] [Crossref]

35. Co O, Lbc C, Mm O, Lbf P, Gf P. Opioids for restless legs syndrome ( Review ). Published online 2016. doi:10.1002/14651858.CD006941.pub2.www.cochranelibrary.com [Google Scholar] [Crossref]

36. Connor JR, Patton S, Oexle K, Allen R. HHS Public Access. Published online 2018:61-70. doi:10.1016/j.sleep.2016.07.028.Iron [Google Scholar] [Crossref]

37. Eick AP Ten, Blumer JL, Reed MD. Safety of Antihistamines in Children. 2001;24(2):119-147. [Google Scholar] [Crossref]

38. Dolder C, Nelson M, Mckinsey J. Use of Non-Benzodiazepine Hypnotics in the Elderly Are All Agents the Same ? 2007;21(5):389-405. [Google Scholar] [Crossref]

39. Sanap, G. S., Dama, G. Y., Hande, A. S., Karpe, S. P., Nalawade, S. V., Kakade, R. S., & Jadhav, U. Y. (2008). Preparation of transdermal monolithic systems of indapamide by solvent casting method and the use of vegetable oils as permeation enhancer G. International Journal of Green Pharmacy (IJGP), 2(2). [Google Scholar] [Crossref]

40. Sanap, G. S., & Mohanta, G. P. (2013). Design and evaluation of miconazole nitrate loaded nanostructured lipid carriers (NLC) for improving the antifungal therapy. Journal of Applied Pharmaceutical Science, 3(1), 046-054. [Google Scholar] [Crossref]

41. Sanap, G. S., Zarekar, N. S., & Pawar, S. S. (2017). Review on method development and validation. International Journal of Pharmaceutics and Drug Analysis, 5(5), 177-184. [Google Scholar] [Crossref]

42. Hondadakatti, R., Shinde, D., Khandelwal, H. R., Pawar, A. K., & Sanap, G. S. (2022). Intranasal Drug Delivery: Novel Delivery Route for Management of Parkinson’s and Depression Neurological Disorders. Letters in Applied NanoBioScience, 11(3), 3640-3651. [Google Scholar] [Crossref]

43. Mirkar, P. P., Pandav, S. S., & Sanap, G. S. (2023). A review on: Diabetes mellitus treatment using herbal drug. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities